We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna. The agreement gives ...

Merck's $11.5 billion deal to acquire Acceleron last year hinged on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has just hit the spot in a much-anticipated ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...